Rilvegostomig

Rilvegostomig is a bispecific humanized IgG1 antibody targeting the immune-regulating receptor programmed cell death protein 1 (PD-1) and the co-inhibitory immune checkpoint molecule T cell immunoreceptor with immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) . It enhances T cell activation, fostering a robust anti-tumor immune response, especially in cancers such as non-small cell lung cancer (NSCLC) . Molecular weight: 146.06 KD.